Clinical Trial Update: TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease [Phase 3]

View source ↗

Summary

This entry notes that the Phase 3 TREND-HD trial of Ethyl-EPA (Miraxion) for Huntington's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Miraxion (Ethyl-EPA)

Snippet

Sponsor: Amarin Neuroscience Ltd | Conditions: Huntington Disease | Phase 3 | Status: COMPLETED